---
title: 'Treatment of agitation in terminally ill patients with intranasal midazolam
  versus subcutaneous midazolam: study protocol for a randomised controlled open-label
  monocentric trial (MinTU Study)'
date: '2024-01-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38172871/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240104170743&v=2.18.0
source: heidelberg[Affiliation]
description: 'BACKGROUND: Intranasal (i.n.) drug application is a widely known and
  low-invasive route of administration that may be able to achieve rapid symptom control
  in terminally ill patients. According to the German S3 guideline "Palliative care
  for patients with incurable cancer", benzodiazepines, such as midazolam, are recommended
  for the treatment of terminal agitation. To the best of our knowledge there is no
  evidence for i.n. midazolam in terminally ill patients. We aim to assess the use
  of ...'
disable_comments: true
---
BACKGROUND: Intranasal (i.n.) drug application is a widely known and low-invasive route of administration that may be able to achieve rapid symptom control in terminally ill patients. According to the German S3 guideline "Palliative care for patients with incurable cancer", benzodiazepines, such as midazolam, are recommended for the treatment of terminal agitation. To the best of our knowledge there is no evidence for i.n. midazolam in terminally ill patients. We aim to assess the use of ...